Cypress Asset Management Inc. TX Trims Stake in Novo Nordisk A/S $NVO

Cypress Asset Management Inc. TX lessened its holdings in Novo Nordisk A/S (NYSE:NVO) by 79.0% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,625 shares of the company’s stock after selling 13,628 shares during the period. Cypress Asset Management Inc. TX’s holdings in Novo Nordisk A/S were worth $201,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Jennison Associates LLC boosted its position in shares of Novo Nordisk A/S by 0.3% during the 2nd quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock valued at $1,303,466,000 after acquiring an additional 63,341 shares during the last quarter. Loomis Sayles & Co. L P lifted its position in Novo Nordisk A/S by 1.5% during the second quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock valued at $867,998,000 after purchasing an additional 187,789 shares during the last quarter. Folketrygdfondet grew its stake in Novo Nordisk A/S by 1.2% in the 3rd quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock worth $566,659,000 after buying an additional 117,370 shares in the last quarter. Sustainable Growth Advisers LP increased its holdings in shares of Novo Nordisk A/S by 11.7% in the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after buying an additional 649,390 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Novo Nordisk A/S by 0.8% in the 2nd quarter. State Street Corp now owns 6,047,683 shares of the company’s stock worth $418,231,000 after buying an additional 47,430 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.2%

NYSE NVO opened at $38.13 on Thursday. The firm has a market cap of $170.24 billion, a PE ratio of 10.99 and a beta of 0.67. Novo Nordisk A/S has a 1-year low of $37.65 and a 1-year high of $91.90. The stock has a 50-day moving average of $53.16 and a 200-day moving average of $53.04. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is presently 23.63%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Strategic deal to pursue oral biologic delivery — Novo agreed to partner with Vivtex in an up-to-$2.1 billion arrangement to develop next‑generation oral medicines for obesity and diabetes, which could expand addressable markets if the technology works. WSJ: Novo Nordisk, Vivtex to Develop Obesity Drugs in Deal Valued at Up to $2.1 Billion
• Positive Sentiment: Promising Phase 2 China data for triple‑agonist UBT251 — a partner trial reported up to 19.7% mean weight loss, supporting Novo’s pipeline diversification beyond semaglutide. This helps offset concern about any single program. Reuters: Novo Nordisk, United Biotechnology obesity drug trial shows 19.7% weight loss
• Positive Sentiment: Short interest fell sharply in February — a nearly 15% drop reduces near-term short‑covering risk and signals some reduced bearish bets against the stock. (Short interest data summary)
• Neutral Sentiment: Commentary framing the sell-off as a potential deep-value opportunity — some analysts and outlets argue the decline creates an entry point, while others caution that structural challenges remain. Benzinga: Novo Nordisk’s 40% Fall May Be Creating A Deep-Value Moment
• Negative Sentiment: Planned U.S. list‑price cuts for Ozempic and Wegovy (up to ~50%) will likely pressure revenue and margins in 2027 and beyond, even if they shore up access and volumes. CNBC: Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S.
• Negative Sentiment: CagriSema trial missed non‑inferiority versus Eli Lilly’s Zepbound, triggering analyst downgrades and a reassessment of Novo’s competitive positioning post‑semaglutide. That clinical setback is a primary driver of the recent sell‑off and lower forecasts. CNBC: Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades
• Negative Sentiment: Multiple sell‑side downgrades and price‑target cuts (including Deutsche Bank/Kepler) are amplifying selling pressure and reducing near‑term analyst support. (Downgrade reports)
• Negative Sentiment: Shareholder litigation inquiry announced by the Schall Law Firm alleging possible misleading statements — adds legal risk and potential distraction. GlobeNewsWire: NVO Investors Have Opportunity to Join Fraud Investigation

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NVO. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday. Citigroup began coverage on Novo Nordisk A/S in a research report on Tuesday, January 27th. They set a “neutral” rating on the stock. CICC Research assumed coverage on Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price for the company. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Six equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $56.07.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.